Who are GTX-102's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qalsody, Amondys 45, Vyondys 53, Exondys 51, Kynamro, PF-07852352 Influenza saRNA 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gtx-102.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GTX-102 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GTX-102 (GTX-102) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense oligonucleotide. Area: Neurology.

phase 3 Antisense oligonucleotide FUS mRNA Neurology Small molecule Live · refreshed every 30 min

Target snapshot

GTX-102 (GTX-102) — Ultragenyx Pharmaceutical Inc. GTX-102 is an antisense oligonucleotide that reduces production of FUS protein by targeting FUS mRNA in patients with FUS-associated neurological disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GTX-102 TARGET	GTX-102	Ultragenyx Pharmaceutical Inc	phase 3	Antisense oligonucleotide	FUS mRNA
Qalsody	TOFERSEN	Biogen Ma	marketed	Antisense Oligonucleotide [EPC]	Superoxide dismutase 1 (SOD1) mRNA	2023-01-01
Amondys 45	CASIMERSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2021-01-01
Vyondys 53	GOLODIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2019-01-01
Exondys 51	ETEPLIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	2016-01-01
Kynamro	MIPOMERSEN	Kastle Theraps Llc	marketed	Antisense Oligonucleotide		2013-01-01
PF-07852352 Influenza saRNA 1	pf-07852352-influenza-sarna-1	Pfizer	marketed	antisense oligonucleotide	influenza virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense oligonucleotide class)

Ionis Pharmaceuticals, Inc. · 3 drugs in this class
Sarepta Therapeutics, Inc. · 2 drugs in this class
Isarna Therapeutics GmbH · 1 drug in this class
Leadiant Biosciences, Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
Avidity Biosciences, Inc. · 1 drug in this class
Ultragenyx Pharmaceutical Inc · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GTX-102 — Competitive Intelligence Brief. https://druglandscape.com/ci/gtx-102. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing